4.7 Article

Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model

期刊

INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 429, 期 1-2, 页码 84-98

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2012.03.019

关键词

Physiological-based pharmacokinetic model of absorption; In vitro-in vivo correlation; In silico-in vivo correlation; Human absolute bioavailability

资金

  1. Fundacao para a Ciencia e a Tecnologia [SFRH/BPD/69748/2010]
  2. Fundação para a Ciência e a Tecnologia [SFRH/BPD/69748/2010] Funding Source: FCT

向作者/读者索取更多资源

Estimates of the human oral absolute bioavailability were made by using a physiological-based pharmacokinetic model of absorption and the drug solubility at the gastrointestinal pH range 1.5-7.5, the apparent permeability (P-app) in Caco-2 cells and the intrinsic clearance (Cl-int) in human hepatocytes suspensions as major drug related parameters. The predictive ability of this approach was tested in 164 drugs divided in four levels of input data: (i) in vitro data for both P-app and Cl-int; (ii) in vitro data for Cl-int only: (iii) in vitro data for P-app only and (iv) in silico data for both P-app and Cl-int. In all scenarios, solubility was estimated in silico. Excellent predictive abilities were observed when in vitro data for both P-app and Cl-int were used, with 84% of drugs with oral bioavailability predictions within a +/- 20% interval of the correct value. This predictive ability is reduced with the introduction of the in silico estimated parameters, particularly when Cl-int is used. Performance of the model using only in silico data provided 53% of drugs with bioavailability predictions within a +/- 20% acceptance interval. However, 74% of drugs in the same scenario resulted in bioavailability predictions within a +/- 35% interval, which indicates that a qualitative prediction of the absolute bioavailability is still possible. This approach is a valuable way to estimate a fundamental pharmacokinetic parameter, using data typically collected in the drug discovery and early development phases, providing also mechanistic information of the limiting bioavailability steps of the drug. (c) 2012 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据